CA3124312A1 - O-linked glycosylation recognition motifs - Google Patents

O-linked glycosylation recognition motifs Download PDF

Info

Publication number
CA3124312A1
CA3124312A1 CA3124312A CA3124312A CA3124312A1 CA 3124312 A1 CA3124312 A1 CA 3124312A1 CA 3124312 A CA3124312 A CA 3124312A CA 3124312 A CA3124312 A CA 3124312A CA 3124312 A1 CA3124312 A1 CA 3124312A1
Authority
CA
Canada
Prior art keywords
seq
comp
amino acid
bioconjugate
glycosylation tag
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3124312A
Other languages
English (en)
French (fr)
Inventor
Christian HARDING
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vaxnewmo LLC
Original Assignee
Vaxnewmo LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxnewmo LLC filed Critical Vaxnewmo LLC
Publication of CA3124312A1 publication Critical patent/CA3124312A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA3124312A 2018-12-21 2019-11-05 O-linked glycosylation recognition motifs Pending CA3124312A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862783971P 2018-12-21 2018-12-21
US62/783,971 2018-12-21
PCT/US2019/059893 WO2020131236A1 (en) 2018-12-21 2019-11-05 O-linked glycosylation recognition motifs

Publications (1)

Publication Number Publication Date
CA3124312A1 true CA3124312A1 (en) 2020-06-25

Family

ID=71101542

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3124312A Pending CA3124312A1 (en) 2018-12-21 2019-11-05 O-linked glycosylation recognition motifs

Country Status (7)

Country Link
US (1) US12350342B2 (cg-RX-API-DMAC7.html)
EP (1) EP3897685B1 (cg-RX-API-DMAC7.html)
JP (2) JP7699543B2 (cg-RX-API-DMAC7.html)
AU (1) AU2019404924B2 (cg-RX-API-DMAC7.html)
CA (1) CA3124312A1 (cg-RX-API-DMAC7.html)
ES (1) ES3055827T3 (cg-RX-API-DMAC7.html)
WO (1) WO2020131236A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10265391B2 (en) 2015-02-26 2019-04-23 Vaxnewmo Llc Acinetobacter O-oligosaccharyltransferases and uses thereof
ES3051337T3 (en) 2018-06-16 2025-12-26 Vaxnewmo Llc Glycosylated comp pilin variants, methods of making and uses thereof
US12350342B2 (en) 2018-12-21 2025-07-08 Vaxnewmo Llc O-linked glycosylation recognition motifs
EP4271417A4 (en) * 2020-12-31 2024-11-27 Vaxnewmo Llc GLYCOSYLATED KLEBSIELLA PNEUMONIAE O-ANTIGEN AND METHODS OF PREPARATION AND USES THEREOF
JP2024517754A (ja) * 2021-04-28 2024-04-23 ヴァックスニューモ エルエルシー O-結合型グリコシル化に十分な最小シークオン
CN115120712B (zh) * 2022-06-30 2025-11-18 中国人民解放军军事科学院军事医学研究院 肺炎链球菌糖蛋白生物结合疫苗及其制备方法和应用
AU2023356184A1 (en) * 2022-10-07 2025-04-17 Vaxnewmo Llc Moraxellaceae o -linking oligosaccharyltransferases, glycosylation fragments, and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US9238830B2 (en) 2006-12-13 2016-01-19 The Governors Of The University Of Alberta Methods and systems for O-glycosylating proteins
US20130196410A1 (en) * 2010-03-05 2013-08-01 Alnylam Pharmaceuticals, Inc Compositions and methods for modifying the glycosylation pattern of a polypeptide
EP2742355B1 (en) 2011-08-12 2018-12-19 The Governors of the University of Alberta Method of diagnosing bacterial infections using bacterial glycoproteins
IN2014CN04076A (cg-RX-API-DMAC7.html) 2011-11-04 2015-10-23 Univ Cornell
KR20150068998A (ko) 2012-10-12 2015-06-22 글리코박신 아게 숙주 세포 변형 방법
EP2917351B1 (en) * 2012-11-07 2018-12-19 GlaxoSmithKline Biologicals S.A. Production of recombinant vaccine in e. coli by enzymatic conjugation
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
JP6356229B2 (ja) 2013-06-04 2018-07-11 アイコン ジェネティクス ゲーエムベーハー 植物産生糖タンパク質及び組換え糖タンパク質のn−グリコシル化部位占有率を調節する方法
US9988426B2 (en) 2014-09-18 2018-06-05 University Of Maryland, Baltimore Broad spectrum conjugate vaccine to prevent Klebsiella pneumoniae and Pseudomonas aeruginosa infections
SI3240895T1 (sl) * 2014-12-30 2022-04-29 Glaxosmithkline Biologicals S.A. Sestavki in postopki za glikozilacijo proteinov
US10265391B2 (en) * 2015-02-26 2019-04-23 Vaxnewmo Llc Acinetobacter O-oligosaccharyltransferases and uses thereof
US11279943B2 (en) * 2017-01-17 2022-03-22 Bioapplications Inc. Recombinant vector for expressing target protein in plant cell
EP3492481A1 (en) 2017-11-30 2019-06-05 Vaxxilon AG Vaccine against klebsiella pneumoniae
ES3051337T3 (en) * 2018-06-16 2025-12-26 Vaxnewmo Llc Glycosylated comp pilin variants, methods of making and uses thereof
JP7551618B2 (ja) 2018-12-12 2024-09-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム O-結合型グリコシル化のための修飾キャリアタンパク質
US12350342B2 (en) 2018-12-21 2025-07-08 Vaxnewmo Llc O-linked glycosylation recognition motifs

Also Published As

Publication number Publication date
JP2025032259A (ja) 2025-03-11
US20220088211A1 (en) 2022-03-24
JP2022514704A (ja) 2022-02-14
WO2020131236A1 (en) 2020-06-25
JP7699543B2 (ja) 2025-06-27
EP3897685A1 (en) 2021-10-27
ES3055827T3 (en) 2026-02-16
AU2019404924A1 (en) 2021-07-08
AU2019404924B2 (en) 2025-09-18
US12350342B2 (en) 2025-07-08
EP3897685A4 (en) 2022-07-27
EP3897685B1 (en) 2025-10-08

Similar Documents

Publication Publication Date Title
US12350342B2 (en) O-linked glycosylation recognition motifs
US12577280B2 (en) Glycosylated comp pilin variants, methods of making and uses thereof
CA2889767C (en) Production of recombinant vaccine in e. coli by enzymatic conjugation
JP7551618B2 (ja) O-結合型グリコシル化のための修飾キャリアタンパク質
JP2023531242A (ja) 改変Exotoxin Aタンパク質
US20240066109A1 (en) Klebsiella Pneumoniae O-Antigen Glycosylated Proteins and Methods of Making and Uses Thereof
US20240207383A1 (en) Minimal Sequons Sufficient for O-Linking Glycosylation
AU2023356184A1 (en) Moraxellaceae o -linking oligosaccharyltransferases, glycosylation fragments, and uses thereof
CN120897997A (zh) 用于生产具有与第二多肽配偶体的异肽键的糖缀合物多肽的组合物和方法以及这些糖缀合物多肽的用途
Mayer et al. A platform for glycoengineering a polyvalent pneumococcal bioconjugate vaccine using E. coli as a host

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220914

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED

Effective date: 20241009

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241104

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241104

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241104

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED

Effective date: 20241112

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250102

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT

Effective date: 20250128

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250128

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250220

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250619

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250627

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251022

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251022

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260423

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260512

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260512

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260528